FYB Stock Overview
Formycon AG develops and markets biosimilar products.
No risks detected for FYB from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||€75.00|
|52 Week High||€75.70|
|52 Week Low||€41.15|
|1 Month Change||15.03%|
|3 Month Change||56.09%|
|1 Year Change||25.00%|
|3 Year Change||129.36%|
|5 Year Change||96.85%|
|Change since IPO||742.70%|
Recent News & Updates
Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|FYB||DE Biotechs||DE Market|
Return vs Industry: FYB exceeded the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: FYB exceeded the German Market which returned -12.9% over the past year.
|FYB Average Weekly Movement||7.0%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: FYB is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: FYB's weekly volatility (7%) has been stable over the past year.
About the Company
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19.
Formycon Fundamentals Summary
|FYB fundamental statistics|
Is FYB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FYB income statement (TTM)|
|Cost of Revenue||€35.96m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.22|
|Net Profit Margin||-36.46%|
How did FYB perform over the long term?See historical performance and comparison
Is Formycon undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FYB (€75) is trading below our estimate of fair value (€632.83)
Significantly Below Fair Value: FYB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FYB is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: FYB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FYB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FYB is overvalued based on its PB Ratio (14.8x) compared to the DE Biotechs industry average (1.5x).
How is Formycon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FYB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).
Earnings vs Market: FYB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FYB's is expected to become profitable in the next 3 years.
Revenue vs Market: FYB's revenue (40.2% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: FYB's revenue (40.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FYB's Return on Equity is forecast to be very high in 3 years time (218.3%).
How has Formycon performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FYB is currently unprofitable.
Growing Profit Margin: FYB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FYB is unprofitable, and losses have increased over the past 5 years at a rate of 40.7% per year.
Accelerating Growth: Unable to compare FYB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: FYB has a negative Return on Equity (-24.03%), as it is currently unprofitable.
How is Formycon's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FYB's short term assets (€38.0M) exceed its short term liabilities (€9.9M).
Long Term Liabilities: FYB's short term assets (€38.0M) exceed its long term liabilities (€372.0K).
Debt to Equity History and Analysis
Debt Level: FYB is debt free.
Reducing Debt: FYB had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FYB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FYB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Formycon current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FYB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Carsten Brockmeyer, PhD, has been Chief Executive Officer and Member of Executive Board at Formycon AG since April 16, 2013 and served as its Chairman of Executive Board. Dr. Brockmeyer has internation...
Experienced Management: FYB's management team is seasoned and experienced (9.1 years average tenure).
Experienced Board: FYB's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Formycon AG's employee growth, exchange listings and data sources
- Name: Formycon AG
- Ticker: FYB
- Exchange: XTRA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €829.856m
- Shares outstanding: 11.06m
- Website: https://www.formycon.com
Number of Employees
- Formycon AG
- Fraunhoferstrasse 15
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.